Prof. A. Ganesan obtained a BSc (Hons) in Chemistry at the
National University of Singapore (1986). He completed his PhD in synthetic
methodology and total synthesis under the supervision of Clayton Heathcock at
the Department of Chemistry, University of California-Berkeley (1992) and was
subsequently a postdoctoral fellow with Gregory Verdine at the Department of
Chemistry at Harvard University. In 1993, he joined the Institute of Molecular
and Cell Biology in Singapore as a Senior Research Chemist at the Centre for
Natural Product Research and in 1996 became Principal Investigator of the
Institute’s Medicinal and Combinatorial Chemistry group. In 1999 he joined the
University of Southampton as a Reader in the Combinatorial Chemistry Centre for
Excellence. In 2011 he became the Chair of Chemical Biology at UEA’s School of
Pharmacy. He is Director of Postgraduate Research and Head of the Healthy
Ageing research theme within the School. He is co-founder of the biotech
company Karus Therapeutics and Chair of the EU COST Action CM1406, 'Epigenetic
Chemical Biology'. He sits on the IUPAC Subcommittee for Medicinal Chemistry
and Drug Development and the Royal Society of Chemistry's Bioorganic &
Medicinal Chemistry Sector committee. His research centres around chemical
biology, medicinal chemistry and organic synthesis with an emphasis on
biologically active natural products and epigenetics.
Prof. A. Ganesan obtained a BSc (Hons) in Chemistry at the
National University of Singapore (1986). He completed his PhD in synthetic
methodology and total synthesis under the supervision of Clayton Heathcock at
the Department of Chemistry, University of California-Berkeley (1992) and was
subsequently a postdoctoral fellow with Gregory Verdine at the Department of
Chemistry at Harvard University. In 1993, he joined the Institute of Molecular
and Cell Biology in Singapore as a Senior Research Chemist at the Centre for
Natural Product Research and in 1996 became Principal Investigator of the
Institute’s Medicinal and Combinatorial Chemistry group. In 1999 he joined the
University of Southampton as a Reader in the Combinatorial Chemistry Centre for
Excellence. In 2011 he became the Chair of Chemical Biology at UEA’s School of
Pharmacy. He is Director of Postgraduate Research and Head of the Healthy
Ageing research theme within the School. He is co-founder of the biotech
company Karus Therapeutics and Chair of the EU COST Action CM1406, 'Epigenetic
Chemical Biology'. He sits on the IUPAC Subcommittee for Medicinal Chemistry
and Drug Development and the Royal Society of Chemistry's Bioorganic &
Medicinal Chemistry Sector committee. His research centres around chemical
biology, medicinal chemistry and organic synthesis with an emphasis on
biologically active natural products and epigenetics.